{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["McDonald MF"],"funding":["The Gene Pennebaker Brain Cancer Fund","The Sweet Family Fund","The Schneider Foundation","The Elias Family Fund","University of Texas MD Anderson Cancer Center","The Jason and Priscilla Hiley Fund","The Bauman Family Curefest Fund","Chuanwei Lu Fund","The Jim &amp; Pam Harris Fund","National Cancer Institute","NCI NIH HHS","Pappas Endowed Fund","The Broach Foundation for Brain Cancer Research","Sorenson Foundation","Brian McCulloch Fund","TLC2 Foundation"],"pagination":["236-250"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10836765"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(2)"],"pubmed_abstract":["<h4>Background</h4>Glioblastoma (GBM) has poor prognosis due to ineffective agents and poor delivery methods. MicroRNAs (miRs) have been explored as novel therapeutics for GBM, but the optimal miRs and the ideal delivery strategy remain unresolved. In this study, we sought to identify the most effective pan-subtype anti-GBM miRs and to develop an improved delivery system for these miRs.<h4>Methods</h4>We conducted an unbiased screen of over 600 miRs against 7 glioma stem cell (GSC) lines representing all GBM subtypes to identify a set of pan-subtype-specific anti-GBM miRs and then used available TCGA GBM patient outcomes and miR expression data to hone in on miRs that were most likely to be clinically effective. To enhance delivery and expression of the miRs, we generated a polycistronic p"],"journal":["Neuro-oncology"],"pubmed_title":["Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma."],"pmcid":["PMC10836765"],"funding_grant_id":["1P50 CA127001","R01 CA214749","P50 CA127001","R01CA115729","R01CA214749"],"pubmed_authors":["Yang J","Daou M","Long L","Parker Kerrigan B","Phillips LM","Lang FF","Momin EN","Hossain A","Ledbetter D","Hasan I","Gopakumar S","Singh S","Adachi S","Gumin J","McDonald MF"],"additional_accession":[]},"is_claimable":false,"name":"Tumor-specific polycistronic miRNA delivered by engineered exosomes for the treatment of glioblastoma.","description":"<h4>Background</h4>Glioblastoma (GBM) has poor prognosis due to ineffective agents and poor delivery methods. MicroRNAs (miRs) have been explored as novel therapeutics for GBM, but the optimal miRs and the ideal delivery strategy remain unresolved. In this study, we sought to identify the most effective pan-subtype anti-GBM miRs and to develop an improved delivery system for these miRs.<h4>Methods</h4>We conducted an unbiased screen of over 600 miRs against 7 glioma stem cell (GSC) lines representing all GBM subtypes to identify a set of pan-subtype-specific anti-GBM miRs and then used available TCGA GBM patient outcomes and miR expression data to hone in on miRs that were most likely to be clinically effective. To enhance delivery and expression of the miRs, we generated a polycistronic p","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Feb","modification":"2026-07-14T19:38:40.081Z","creation":"2025-04-04T20:55:45.093Z"},"accession":"S-EPMC10836765","cross_references":{"pubmed":["37847405"],"doi":["10.1093/neuonc/noad199"]}}